Immix Biopharma (IMMX) Depreciation & Amortization (CF) (2021 - 2026)
Immix Biopharma (IMMX) reported Depreciation & Amortization (CF) of $91577.0 for Q1 2026, up 140.03% on a YoY basis from $38153.0 in Q1 2025, and up 75.72% sequentially from $52114.0 in Q4 2025.
Immix Biopharma (IMMX) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $91577.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 140.03% year-over-year to $91577.0; the trailing twelve-month figure through Mar 2026 stood at $299171.0 (up 339.41% YoY), and the FY2025 full-year result was $245747.0, up 646.02% from the prior year.
- Depreciation & Amortization (CF) climbed to $91577.0 in Q1 2026, from $52114.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $96986.0 in Q3 2025 to a low of $383.0 in Q2 2022.
- A 5-year average of $22227.5 and a median of $3076.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) plunged 38.23% in 2022 and surged 1679.89% in 2025, its largest moves.
- Tracing IMMX's Depreciation & Amortization (CF) over 5 years: stood at $566.0 in 2022, then surged by 443.46% to $3076.0 in 2023, then soared by 569.8% to $20603.0 in 2024, then surged by 152.94% to $52114.0 in 2025, then surged by 75.72% to $91577.0 in 2026.
- Business Quant data shows IMMX's Depreciation & Amortization (CF) at $91577.0 in Q1 2026, $52114.0 in Q4 2025, and $96986.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Immix Biopharma | 473.68 Mn | 473.68 Mn | - | 91,577.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91,577.00 |
| Mar 31, 2026 | 91,577.00 |
| Dec 31, 2025 | 52,114.00 |
| Dec 31, 2025 | 52,114.00 |
| Sep 30, 2025 | 96,986.00 |
| Sep 30, 2025 | 96,986.00 |
| Jun 30, 2025 | 58,494.00 |
| Jun 30, 2025 | 58,494.00 |
| Mar 31, 2025 | 38,153.00 |
| Mar 31, 2025 | 38,153.00 |
| Dec 31, 2024 | 20,603.00 |
| Dec 31, 2024 | 20,603.00 |
| Sep 30, 2024 | 5,449.00 |
| Sep 30, 2024 | 5,449.00 |
| Jun 30, 2024 | 3,879.00 |
| Jun 30, 2024 | 3,879.00 |
| Mar 31, 2024 | 3,010.00 |
| Mar 31, 2024 | 3,010.00 |
| Dec 31, 2023 | 3,076.00 |
| Dec 31, 2023 | 3,076.00 |